Payment overview · 2025
General Payments
$59.44
3 reported records · 3 companies
Healthcare provider profile · identity verified
Sydney Lance Hendrix, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JESUP, GA · NPI 1679643712
Verified facts
What the public records show
CMS Open Payments records show Sydney Lance Hendrix, M.D. received $59.44 in general payments during 2025 across 3 reported records.
PFIZER INC. accounted for 40.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 442 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.94 | 40.3% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $19.16 | 32.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.34 | 27.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $59.44 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 442 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
179 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
46 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
442 | 81 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 921 | 236 |
| Levothyroxine Sodium | Levothyroxine Sodium | 796 | 172 |
| Amlodipine Besylate | Amlodipine Besylate | 789 | 193 |
| Pantoprazole Sodium | Pantoprazole Sodium | 618 | 148 |
| Losartan Potassium | Losartan Potassium | 525 | 132 |
| Omeprazole | Omeprazole | 487 | 116 |
| Gabapentin | Gabapentin | 483 | 117 |
| Lisinopril | Lisinopril | 444 | 126 |
| Eliquis | Apixaban | 442 | 81 |
| Metformin Hcl | Metformin Hcl | 417 | 104 |
| Metoprolol Tartrate | Metoprolol Tartrate | 405 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 379 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 365 | 80 |
| Tramadol Hcl | Tramadol Hcl | 303 | 51 |
| Simvastatin | Simvastatin | 300 | 77 |
| Furosemide | Furosemide | 272 | 71 |
| Duloxetine Hcl | Duloxetine Hcl | 270 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 266 | 67 |
| Trazodone Hcl | Trazodone Hcl | 264 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 263 | 66 |
| Allopurinol | Allopurinol | 254 | 67 |
| Potassium Chloride | Potassium Chloride | 247 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 211 | 56 |
| Atenolol | Atenolol | 204 | 45 |
| Famotidine | Famotidine | 202 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 49 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 196 | 60 |
| Alprazolam | Alprazolam | 184 | 33 |
| Ozempic | Semaglutide | 179 | 40 |
| Sertraline Hcl | Sertraline Hcl | 173 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 172 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 161 | 40 |
| Doxazosin Mesylate | Doxazosin Mesylate | 159 | 42 |
| Synthroid | Levothyroxine Sodium | 157 | 37 |
| Lovastatin | Lovastatin | 155 | 34 |
| Alendronate Sodium | Alendronate Sodium | 151 | 36 |
| Clonazepam | Clonazepam | 151 | 16 |
| Montelukast Sodium | Montelukast Sodium | 144 | 36 |
| Donepezil Hcl | Donepezil Hcl | 142 | 26 |
| Prednisone | Prednisone | 129 | 97 |
| Paroxetine Hcl | Paroxetine Hcl | 127 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 48 |
| Meloxicam | Meloxicam | 121 | 32 |
| Trulicity | Dulaglutide | 112 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 110 | 26 |
| Mirtazapine | Mirtazapine | 104 | 28 |
| Carvedilol | Carvedilol | 99 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 99 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 92 | 13 |
| Lorazepam | Lorazepam | 91 | 18 |
| Warfarin Sodium | Warfarin Sodium | 91 | 18 |
| Buspirone Hcl | Buspirone Hcl | 90 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 21 |
| Cephalexin | Cephalexin | 88 | 64 |
| Ezetimibe | Ezetimibe | 84 | 22 |
| Jardiance | Empagliflozin | 82 | 20 |
| Azelastine Hcl | Azelastine Hcl | 78 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 72 | 39 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 16 |
| Bupropion Xl | Bupropion Hcl | 70 | 13 |
| Clonidine Hcl | Clonidine Hcl | 69 | 13 |
| Celecoxib | Celecoxib | 67 | 17 |
| Glipizide | Glipizide | 66 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 58 | 13 |
| Enalapril Maleate | Enalapril Maleate | 57 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 54 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 13 |
| Spironolactone | Spironolactone | 52 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 51 | 11 |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 37 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 46 | 46 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 41 |
| Metformin Hcl Er | Metformin Hcl | 46 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 38 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 32 |
| Meclizine Hcl | Meclizine Hcl | 44 | 17 |
| Benazepril Hcl | Benazepril Hcl | 43 | suppressed |
| Glipizide Er | Glipizide | 43 | 11 |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 12 |
| Finasteride | Finasteride | 39 | 13 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 38 | suppressed |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 13 |
| Glimepiride | Glimepiride | 33 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 33 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 31 | 31 |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 19 |
| Cefdinir | Cefdinir | 29 | 28 |
| Olanzapine | Olanzapine | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Azithromycin | Azithromycin | 28 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Nadolol | Nadolol | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | 12 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Nystatin | Nystatin | 19 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 14 |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Telmisartan | Telmisartan | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Tirosint | Levothyroxine Sodium | 13 | suppressed |
| Alprazolam Er | Alprazolam | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $59.44 · 3 records | PFIZER INC. | ECC Solutions, ELIQUIS, NURTEC ODT, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error